Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.
about
Revisiting the hallmarks of cancer.One microenvironment does not fit all: heterogeneity beyond cancer cells.Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications.A new mild hyperthermia device to treat vascular involvement in cancer surgery.Fatal attraction: TICs and MDSCs.Generation of an in vitro 3D PDAC stroma rich spheroid model.Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment.Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response.mTOR at the Transmitting and Receiving Ends in Tumor Immunity.Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.Immune Landscape of Breast Cancers.Alterations of Signaling Pathways Related to the Immune System in Breast Cancer: New Perspectives in Patient ManagementThe paradoxical functions of EGFR during breast cancer progressionFGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation InitiationLocal angiotensin II contributes to tumor resistance to checkpoint immunotherapyp21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulationRole of mTOR Signaling in Tumor Microenvironment: An Overview
P2860
Q33732986-2BD66C8D-155C-45E5-B1DE-6B0A58B7AC3DQ39011826-0FFA7F9D-B213-47E3-AABD-9246C284F584Q39197682-B35431BE-E851-4F2D-9BFC-8F471AB11FC6Q41198521-CFD65DB3-8510-497D-8BE1-64E0B72A9E0CQ41352761-3DEFDA2F-89F0-4256-80F3-0967F2C1BDF0Q42678442-76C76986-AC9B-4E6D-BA3D-04A4263452F9Q48193673-7AAF2A3E-2D30-4D59-9287-11D8FB40DB7DQ48308089-D5DFC7CB-2693-4406-846C-368F6D534814Q51840300-E2F1046E-F306-461B-B7DC-E5E9992C763DQ52319565-8A3D0900-BAA8-46E6-94A0-0B9AC18AB0D0Q54111915-E036EF1F-6859-426B-A4CD-DCF2040C978CQ54117923-CAF2D3A0-EF06-4506-BDCB-7B5AB1D4C742Q55032160-0439A649-5D4B-4DA2-94BC-5ABE82C47F8DQ57106000-D96D62B4-63F8-4B3F-A863-6D0D4CF6D284Q57118645-C3153525-FF91-42F9-BDC9-07BA111521E3Q57753454-DC1CE4C5-E188-469D-A50F-FBADC202C0F9Q58748151-B28C2285-27D3-4956-ABA5-BCEE0F059A43Q58760423-AA927E22-DB23-4A54-8FB5-66D277C434CBQ58766017-FE432402-4601-4A87-A68F-2FED6219469E
P2860
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Oncogenic mTOR signalling recr ...... to promote tumour initiation.
@en
type
label
Oncogenic mTOR signalling recr ...... to promote tumour initiation.
@en
prefLabel
Oncogenic mTOR signalling recr ...... to promote tumour initiation.
@en
P2093
P2860
P50
P356
P1433
P1476
Oncogenic mTOR signalling recr ...... to promote tumour initiation.
@en
P2093
Dean P Edwards
Ik Sun Kim
Jason I Herschkowitz
Jeffrey M Rosen
Jianming Xu
Lacey E Dobrolecki
P2860
P2888
P304
P356
10.1038/NCB3355
P577
2016-05-16T00:00:00Z